Statins May Slow Multiple Sclerosis Progression Full Text
U.S. Pharmacist, 06/10/2010
A study examining the impact of statins on the progression of multiple sclerosis (MS) found a lower incidence of new brain lesions in patients with early–stage disease who received an 80–mg daily dose of atorvastatin over 12 months. The randomized, placebo–controlled study was conducted by researchers at the University of California–San Francisco. Although the study was small and its primary endpoint—to evaluate MS progression in patients following their first attack—was not met, 55.3% of the statin group did not develop new brain lesions, versus 27.6% of the placebo group.